HROW vs. ERAS, MREO, RANI, ADCT, AMRN, TERN, ANRO, NATR, CRBP, and MRSN
Should you be buying Harrow stock or one of its competitors? The main competitors of Harrow include Erasca (ERAS), Mereo BioPharma Group (MREO), Rani Therapeutics (RANI), ADC Therapeutics (ADCT), Amarin (AMRN), Terns Pharmaceuticals (TERN), Alto Neuroscience (ANRO), Nature's Sunshine Products (NATR), Corbus Pharmaceuticals (CRBP), and Mersana Therapeutics (MRSN). These companies are all part of the "pharmaceutical preparations" industry.
Harrow (NASDAQ:HROW) and Erasca (NASDAQ:ERAS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.
Harrow has higher revenue and earnings than Erasca. Harrow is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks.
In the previous week, Erasca had 4 more articles in the media than Harrow. MarketBeat recorded 6 mentions for Erasca and 2 mentions for Harrow. Erasca's average media sentiment score of 0.04 beat Harrow's score of 0.00 indicating that Erasca is being referred to more favorably in the news media.
Harrow received 63 more outperform votes than Erasca when rated by MarketBeat users. However, 61.54% of users gave Erasca an outperform vote while only 55.63% of users gave Harrow an outperform vote.
72.8% of Harrow shares are owned by institutional investors. Comparatively, 67.8% of Erasca shares are owned by institutional investors. 13.6% of Harrow shares are owned by insiders. Comparatively, 29.8% of Erasca shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Erasca has a net margin of 0.00% compared to Harrow's net margin of -18.75%. Harrow's return on equity of -29.48% beat Erasca's return on equity.
Harrow presently has a consensus price target of $28.13, suggesting a potential upside of 161.71%. Erasca has a consensus price target of $7.83, suggesting a potential upside of 318.89%. Given Erasca's higher possible upside, analysts clearly believe Erasca is more favorable than Harrow.
Harrow has a beta of 0.58, suggesting that its stock price is 42% less volatile than the S&P 500. Comparatively, Erasca has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500.
Summary
Erasca beats Harrow on 9 of the 17 factors compared between the two stocks.
Get Harrow News Delivered to You Automatically
Sign up to receive the latest news and ratings for HROW and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HROW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
